Key Points
-
Hepatocyte growth factor (HGF) and its tyrosine kinase receptor MET (also known as HGF receptor) mediate invasive growth, a complex programme in which cells lose contacts with their neighbours, mobilize towards adjacent surroundings, resist apoptotic insults and proliferate.
-
During development, HGF and MET are essential for the growth and survival of epithelial cell types and for the migration of muscle progenitors. In adult physiology, MET exerts a trophic activity that attenuates tissue damage and promotes the regeneration of several organs.
-
In tumours, MET stimulates the motility and survival of cancer cells as well as angiogenesis, thereby acting as a powerful expedient for neoplastic invasion and production of secondary metastases. MET gain-of-function genetic lesions can also be selected to maintain the transformed phenotype of some primary tumours, which seem to be 'addicted' to continued MET activity for their relentless growth.
-
MET signals are channelled by an unconventional multifunctional docking site consisting of two tyrosines that, when phosphorylated, recruit a wide spectrum of transducers. Interaction with the GRB2-associated-binding protein 1 (GAB1) multi-adaptor protein is critical for transduction of most MET signalling pathways, whereas tissue-specific interactions with other surface partners such as the α6β4 integrin and the CD44 adhesion molecule regulate quantitative modulation of downstream signalling and cytoskeletal compartmentalization, respectively.
-
MET signals emanate not only from the plasma membrane but also from endosomal compartments, and MET internalization seems to be required for efficient activation and proper subcellular localization of distal transducers such as extracellular signal-regulated kinases (ERKs) and signal transducer and activator of transcription 3 (STAT3). MET also undergoes other trafficking events — including extracellular shedding, intracellular cleavage, ubiquitylation, degradation and membrane recycling — which regulate the strength of MET activation and the ensuing robustness of MET-dependent signals.
-
In distinct cells and tissues, specific activities that are controlled by MET seem to be fulfilled by dedicated signalling cascades, with some transducers dominating over others according to context, timing and biological complexity. This suggests that the specificity of MET-dependent responses is determined, at least in part, by qualitative differences in signalling outputs.
Abstract
The MET tyrosine kinase receptor (also known as the HGF receptor) promotes tissue remodelling, which underlies developmental morphogenesis, wound repair, organ homeostasis and cancer metastasis, by integrating growth, survival and migration cues in response to environmental stimuli or cell-autonomous perturbations. The versatility of MET-mediated biological responses is sustained by qualitative and quantitative signal modulation. Qualitative mechanisms include the engagement of dedicated signal transducers and the subcellular compartmentalization of MET signalling pathways, whereas quantitative regulation involves MET partnering with adaptor amplifiers or being degraded through the shedding of its extracellular domain or through intracellular ubiquitylation. Controlled activation of MET signalling can be exploited in regenerative medicine, whereas MET inhibition might slow down tumour progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bryant, D. M. & Mostov, K. E. From cells to organs: building polarized tissue. Nature Rev. Mol. Cell Biol. 9, 887–901 (2008).
Gurtner, G. C., Werner, S., Barrandon, Y. & Longaker, M. T. Wound repair and regeneration. Nature 453, 314–321 (2008).
Frisch, S. M. & Screaton, R. A. Anoikis mechanisms. Curr. Opin. Cell Biol. 13, 555–562 (2001).
Lu, P. & Werb, Z. Patterning mechanisms of branched organs. Science 322, 1506–1509 (2008).
Zaret, K. S. & Grompe, M. Generation and regeneration of cells of the liver and pancreas. Science 322, 1490–1494 (2008).
Schäfer, M. & Werner, S. Cancer as an overhealing wound: an old hypothesis revisited. Nature Rev. Mol. Cell Biol. 9, 628–638 (2008).
Yang, J. & Weinberg, R. A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 14, 818–829 (2008).
Christofori, G. New signals from the invasive front. Nature 441, 444–450 (2006).
Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420–1428 (2009).
Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871–890 (2009).
Park, M. et al. Mechanism of met oncogene activation. Cell 45, 895–904 (1986).
Giordano, S., Ponzetto, C., Di Renzo, M. F., Cooper, C. S. & Comoglio, P. M. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 339, 155–156 (1989).
Stoker, M., Gherardi, E., Perryman, M. & Gray, J. Scatter factor is a fibroblast-derived modulator of epithelial cell motility. Nature 327, 239–242 (1987).
Nakamura, T. et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 342, 440–443 (1989).
Zarnegar, R. & Michalopoulos, G. Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res. 49, 3314–3320 (1989).
Bottaro, D. P. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802–804 (1991).
Montesano, R., Matsumoto, K., Nakamura, T. & Orci, L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67, 901–908 (1991).
Naldini, L. et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 6, 501–504 (1991).
Naldini, L. et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 10, 2867–2878 (1991).
Weidner, K. M. et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl Acad. Sci. USA 88, 7001–7005 (1991).
Birchmeier, C. & Gherardi, E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 8, 404–410 (1998).
Birchmeier, C., Birchmeier, W., Gherardi, E. & Vande Woude, G. F. Met, metastasis, motility and more. Nature Rev. Mol. Cell Biol. 4, 915–925 (2003).
Comoglio, P. M., Giordano, S. & Trusolino, L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Rev. Drug Discov. 7, 504–516 (2008).
Trusolino, L. & Comoglio, P. M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature Rev. Cancer 2, 289–300 (2002).
Lai, A. Z., Abella, J. V. & Park, M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol. 19, 542–551 (2009).
Furge, K. A., Zhang, Y. W. & Vande Woude, G. F. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 19, 5582–5589 (2000).
Zhang, Y. W. & Vande Woude, G. F. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J. Cell. Biochem. 88, 408–417 (2003).
Gao, C. F. & Vande Woude, G. F. HGF/SF-Met signaling in tumor progression. Cell Res. 15, 49–51 (2005).
Peschard, P. & Park, M. From Tpr–Met to Met, tumorigenesis and tubes. Oncogene 26, 1276–1285 (2007).
Kobayashi, T. et al. Hepatocyte growth factor specifically binds to sulfoglycolipids. J. Biol. Chem. 269, 9817–9821 (1994).
Lyon, M., Deakin, J. A., Mizuno, K., Nakamura, T. & Gallagher, J. T. Interaction of hepatocyte growth factor with heparan-sulfate. Elucidation of the major heparan sulfate structural determinants. J. Biol. Chem. 269, 11216–11223 (1994).
Sonnenberg, E., Meyer, D., Weidner, K. M. & Birchmeier, C. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J. Cell Biol. 123, 223–235 (1993).
Michalopoulos, G. K. & DeFrances, M. C. Liver regeneration. Science 276, 60–66 (1997).
Bhowmick, N. A., Neilson, E. G. & Moses, H. L. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332–337 (2004).
Mars, W. M., Zarnegar, R. & Michalopoulos, G. K. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am. J. Pathol. 143, 949–958 (1993).
Owen, K. A. et al. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem. J. 426, 219–228 (2010).
Ponzetto, C. et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77, 261–271 (1994).
Palka, H. L., Park, M. & Tonks, N. K. Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. J. Biol. Chem. 278, 5728–5735 (2003).
Machide, M., Hashigasako, A., Matsumoto, K. & Nakamura, T. Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase. J. Biol. Chem. 281, 8765–8772 (2006).
Sangwan, V. et al. Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase. J. Biol. Chem. 283, 34374–34383 (2008).
Bertotti, A. & Comoglio, P. M. Tyrosine kinase signal specificity: lessons from the HGF receptor. Trends Biochem. Sci. 28, 527–533 (2003).
Sipeki, S. et al. Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. Cell Signal. 11, 885–890 (1999).
Maroun, C. R. et al. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol. 19, 1784–1799 (1999).
Maroun, C. R., Naujokas, M. A., Holgado-Madruga, M., Wong, A. J. & Park, M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol. 20, 8513–8525 (2000).
Pelicci, G. et al. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene 10, 1631–1638 (1995).
Fixman, E. D., Fournier, T. M., Kamikura, D. M., Naujokas, M. A. & Park M. Pathways downstream of Shc and Grb2 are required for cell transformation by the Tpr–Met oncoprotein J. Biol. Chem. 271, 13116–13122 (1996).
Boccaccio, C. et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391, 285–288 (1998).
Zhang, Y. W., Wang, L. M., Jove, R. & Vande Woude, G. F. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 21, 217–226 (2002).
Weidner, K. M. et al. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384, 173–176 (1996).
Garcia-Guzman, M., Dolfi, F., Zeh, K. & Vuori, K. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1–Crk signaling complex formation. Oncogene 18, 7775–7786 (1999).
Schaeper, U. et al. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J. Cell Biol. 149, 1419–1432 (2000).
Gual, P. et al. Sustained recruitment of phospholipase c-γ to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 19, 1509–1518 (2000).
Montagner, A. et al. A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation. J. Biol. Chem. 280, 5350–5360 (2005).
Lock, L. S., Royal, I., Naujokas, M. A. & Park, M. Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases. J. Biol. Chem. 275, 31536–31545 (2000).
Comoglio, P. M., Boccaccio, C. & Trusolino, L. Interactions between growth factor receptors and adhesion molecules: breaking the rules. Curr. Opin. Cell Biol. 15, 565–571 (2003).
Trusolino, L., Bertotti, A. & Comoglio, P. M. A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth. Cell 107, 643–654 (2001).
Bertotti, A., Comoglio, P. M. & Trusolino, L. β4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res. 65, 10674–10679 (2005).
Bertotti, A., Comoglio, P. M. & Trusolino, L. β4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. J. Cell Biol. 175, 993–1003 (2006).
Ponta, H., Sherman, L. & Herrlich, P. A. CD44: from adhesion molecules to signalling regulators. Nature Rev. Mol. Cell Biol. 4, 33–45 (2003).
Orian-Rousseau, V., Chen, L., Sleeman, J. P., Herrlich, P. & Ponta, H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 16, 3074–3086 (2002).
Orian-Rousseau, V. et al. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol. Biol. Cell 18, 76–83 (2007).
Singleton, P. A. et al. CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J. Biol. Chem. 282, 30643–30657 (2007).
Giordano, S. et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nature Cell Biol. 4, 720–724 (2002).
Conrotto, P., Corso, S., Gamberini, S., Comoglio, P. M. & Giordano, S. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 23, 5131–5137 (2004).
Conrotto, P. et al. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 105, 4321–4329 (2005). References 56–65 provide information on how MET-dependent signals can be tuned by the association of MET with surface transmembrane partners, including β4 integrin, CD44 and plexin B.
Capparuccia, L. & Tamagnone, L. Semaphorin signaling in cancer cells and in cells of the tumor microenvironment — two sides of a coin. J. Cell Sci. 122, 1723–1736 (2009).
Johnson, G. L. & Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911–1912 (2002).
Stella, M. C., Trusolino, L., Pennacchietti, S. & Comoglio, P. M. Negative feedback regulation of Met-dependent invasive growth by Notch. Mol. Cell. Biol. 25, 3982–3996 (2005).
Lee, C. C. et al. Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene 23, 5193–5202 (2004).
Rodrigues, G. A., Park, M. & Schlessinger, J. Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J. 16, 2634–2645 (1997).
Lamorte, L., Kamikura, D. M. & Park, M. A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein. Oncogene 19, 5973–5981 (2000).
Recio, J. A. & Merlino, G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 21, 1000–1008 (2002).
Rasola, A. et al. Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res. 64, 1744–1750 (2004).
Coltella, N. et al. p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. Int. J. Cancer 118, 2981–2990 (2006).
Karin, M., Cao, Y., Greten, F. R. & Li, Z. W. NF-κB in cancer: from innocent bystander to major culprit. Nature Rev. Cancer 2, 301–310 (2002).
Fan, S. et al. Role of NF-κB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 24, 1749–1766 (2005).
Müller, M., Morotti, A. & Ponzetto, C. Activation of NF-κB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol. Cell. Biol. 22, 1060–1072 (2002).
Scita, G. & Di Fiore, P. P. The endocytic matrix. Nature 463, 464–473 (2010).
Kermorgant, S. & Parker, P. J. c-Met signaling: spatiotemporal decisions. Cell Cycle 4, 352–355 (2005).
Liu, Z. X., Yu, C. F., Nickel, C., Thomas, S. & Cantley, L. G. Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin–focal adhesion kinase association. J. Biol. Chem. 277, 10452–10458 (2002).
Kermorgant, S., Zicha, D. & Parker, P. J. PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J. 23, 3721–3734 (2004).
Rosse, C. et al. PKC and the control of localized signal dynamics. Nature Rev. Mol. Cell Biol. 11, 103–112 (2010).
Kermorgant, S., Zicha, D. & Parker, P. J. Protein kinase C controls microtubule-based traffic but not proteasomal degradation of c-Met. J. Biol. Chem. 278, 28921–28929 (2003).
Kermorgant, S. & Parker, P. J. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J. Cell Biol. 182, 855–863 (2008).
Sorkin, A. & von Zastrow, M. Endocytosis and signalling: intertwining molecular networks. Nature Rev. Mol. Cell Biol. 10, 609–622 (2009).
Peschard, P. et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995–1004 (2001).
Carter, S., Urbé, S. & Clague, M. J. The met receptor degradation pathway: requirement for Lys48-linked polyubiquitin independent of proteasome activity. J. Biol. Chem. 279, 52835–52839 (2004).
Hammond, D. E., Urbé, S., Vande Woude, G. F. & Clague, M. J. Down-regulation of Met, the receptor for hepatocyte growth factor. Oncogene 20, 2761–2770 (2001).
Li, N., Xiang, G. S., Dokainish, H., Ireton, K. & Elferink, L. A. The Listeria protein internalin B mimics hepatocyte growth factor-induced receptor trafficking. Traffic 6, 459–473 (2005).
Oved, S. & Yarden, Y. Signal transduction: molecular ticket to enter cells. Nature 416, 133–136 (2002).
Petrelli, A. et al. The endophilin–CIN85–Cbl complex mediates ligand-dependent downregulation of c-Met. Nature 416, 187–190 (2002).
Goldoni, S. et al. Decorin is a novel antagonistic ligand of the Met receptor. J. Cell Biol. 185, 743–754 (2009).
Polo, S. & Di Fiore, P. P. Endocytosis conducts the cell signaling orchestra. Cell 124, 897–900 (2006).
Foveau, B. et al. Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol. Biol. Cell. 20, 2495–2507 (2009).
Prat, M. et al. C-terminal truncated forms of Met, the hepatocyte growth factor receptor. Mol. Cell. Biol. 11, 5954–5962 (1991).
Galvani, A. P., Cristiani, C., Carpinelli, P., Landonio, A. & Bertolero, F. Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form. Biochem. Pharmacol. 50, 959–966 (1995).
Nath, D., Williamson, N. J., Jarvis, R. & Murphy, G. Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J. Cell Sci. 114, 1213–1220 (2001).
Wajih, N., Walter, J. & Sane, D. C. Vascular origin of a soluble truncated form of the hepatocyte growth factor receptor (c-met). Circ. Res. 90, 46–52 (2002).
Petrelli, A. et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc. Natl Acad. Sci. USA 103, 5090–5095 (2006).
Schelter, F. et al. A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J. Biol. Chem. 285, 26335–26340 (2010).
Vigna, E. et al. “Active” cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res. 68, 9176–9183 (2008).
Pacchiana, G. et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J. Biol. Chem. 285, 36149–36157 (2010).
Michieli, P. et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6, 61–73 (2004).
Zhang, Y. W., Graveel, C., Shinomiya, N. & Vande Woude, G. F. Met decoys: will cancer take the bait? Cancer Cell 6, 5–6 (2004).
Barabasi, A.-L. & Oltavi, Z. N. Network biology: understanding the cell's functional organization. Nature Rev. Genet. 5, 101–113 (2004).
Schmidt, C. et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373, 699–702 (1995).
Uehara, Y. et al. Placental defect and embryonal lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373, 702–705 (1995).
Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A. & Birchmeier, C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376, 768–771 (1995).
Birchmeier, C. & Gherardi, E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 8, 404–410 (1998).
Maina, F., Hilton, M. C., Ponzetto, C., Davies, A. M. & Klein, R. Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons. Genes Dev. 11, 3341–3350 (1997).
Maina, F. et al. Multiple roles for hepatocyte growth factor in sympathetic neuron development. Neuron 20, 835–846 (1998).
Helmbacher, F. et al. Met signaling is required for recruitment of motor neurons to PEA3-positive motor neurons. Neuron 39, 767–777 (2003).
Maina, F. et al. Coupling Met to specific pathways results in distinct developmental outcomes. Mol. Cell 7, 1293–1306 (2001). This article addresses in vivo how activation of individual MET-dependent signalling pathways influences the execution of specific biological responses.
Sachs, M. et al. Essential role of Gab1 for signaling by the c-Met receptor in vivo. J. Cell Biol. 150, 1375–1384 (2000).
Schaeper, U. et al. Distinct requirements for Gab1 in Met and EGF receptor signaling in vivo. Proc. Natl Acad. Sci. USA 104, 15376–15381 (2007). The authors show that the multi-adaptor GAB1 promotes different biological outcomes in vivo through the recruitment of distinct effectors.
Debnath, J. & Brugge, J. S. Modelling glandular epithelial cancers in three-dimensional cultures. Nature Rev. Cancer 5, 675–688 (2005).
Rosário, M. & Birchmeier, W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol. 13, 328–335 (2003).
O'Brien, L. E. et al. ERK and MMPs sequentially regulate distinct stages of epithelial tubule development. Dev. Cell 7, 21–32 (2004). A mechanistic dissection, using three-dimensional culture models, of the signalling pathways that mediate the sequential steps of MET-induced epithelial tubulogenesis.
Rosário, M. & Birchmeier, W. Making tubes: step by step. Dev. Cell 7, 3–5 (2004).
Leroy, P. & Mostov, K. E. Slug is required for cell survival during partial epithelial-mesenchymal transition of HGF-induced tubulogenesis. Mol. Biol. Cell 18, 1943–1952 (2007).
Rosenthal, E. L. et al. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res. 58, 5221–5230 (1998).
Nabeshima, K. et al. Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/scatter factor. Cancer Res. 60, 3364–3369 (2000).
Monvoisin, A. et al. Involvement of matrix metalloproteinase type-3 in hepatocyte growth factor-induced invasion of human hepatocellular carcinoma cells. Int. J. Cancer 97, 157–162 (2002).
Miyazawa, K. et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem. Biophys. Res. Commun. 163, 967–973 (1989).
Huh, C. G. et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl Acad. Sci. USA 101, 4477–4482 (2004).
Borowiak, M. et al. Met provides essential signals for liver regeneration. Proc. Natl Acad. Sci. USA 101, 10608–10613 (2004). References 125 and 126 describe the first genetic demonstrations that MET is essential in the regeneration of adult liver.
Bard-Chapeau, E. A. et al. Concerted functions of Gab1 and Shp2 in liver regeneration and hepatoprotection. Mol. Cell. Biol. 26, 4664–4674 (2006).
Liu, Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am. J. Physiol. Renal Physiol. 287, F7–F16 (2004).
Wynn, T. A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199–210 (2008).
Ueki, T. et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nature Med. 5, 226–230 (1999).
Yang, J., Dai, C. & Liu, Y. Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am. J. Pathol. 163, 621–632 (2003).
Dai, C. & Liu, Y. Hepatocyte growth factor antagonizes the profibrotic action of TGF-β1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J. Am. Soc. Nephrol. 15, 1402–1412 (2004).
Kim, W. H., Matsumoto, K., Bessho, K. & Nakamura, T. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am. J. Pathol. 166, 1017–1028 (2005).
Blanpain, C. & Fuchs, E. Epidermal homeostasis: a balancing act of stem cells in the skin. Nature Rev. Mol. Cell Biol. 10, 207–217 (2009).
Chmielowiec, J. et al. c-Met is essential for wound healing in the skin. J. Cell Biol. 177, 151–162 (2007).
Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347–361 (2003).
Giordano, S. et al. A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proc. Natl Acad. Sci. USA 94, 13868–13872 (1997).
Bardelli, A. et al. Concomitant activation of pathways downstream of Grb2 and PI3-kinase is required for MET-mediated metastasis. Oncogene 18, 1139–1146 (1999).
Ma, P. C. et al. Downstream signalling and specific inhibition of c-Met/HGF pathway in small cell lung cancer: implications for tumour invasion. Br. J. Cancer 97, 368–377 (2007).
Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genet. 16, 68–73 (1997).
Stella, G. M. et al. MET mutations in cancers of unknown primary origin. Hum. Mutat. 14 Oct 2010 (doi:10.1002/humu.21374).
Smolen, G. A. et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl Acad. Sci. USA 103, 2316–2321 (2006).
McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936–19941 (2007). References 142 and 143 are the first demonstration that only cell lines with amplification of the Met gene respond to MET inhibition with substantial growth impairment.
Guo, A. et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl Acad. Sci. USA 105, 692–697 (2008).
Bertotti, A. et al. Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci. Signal. 2, ra80 (2009). References 144 and 145 are the first large-scale analyses of the signalling and transcriptional consequences of MET inhibition in drug-sensitive, MET-addicted cell lines.
Bertotti, A. et al. Inhibition of Src impairs the growth of Met-addicted gastric tumors. Clin. Cancer Res. 16, 3933–3943 (2010).
Amit, I. et al. A module of negative feedback regulators defines growth factor signaling. Nature Genet. 39, 503–512 (2007).
Jeffrey, K. L., Camps, M., Rommel, C. & Mackay, C. R. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nature Rev. Drug Discov. 6, 391–403 (2007).
Kim, S. et al. MicroRNA mir199-a regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J. Biol. Chem. 283, 18158–18166 (2008).
Migliore, C. et al. MicroRNAs impair MET-mediated invasive growth. Cancer Res. 68, 10128–10136 (2008).
Taulli, R. et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J. Clin. Invest. 119, 2366–2378 (2009).
Garofalo, M. et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16, 498–509 (2009).
Fornari, F. et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 70, 5184–5193 (2010).
Bradbury, J. A two-pronged approach to the clinical use of HGF. Lancet 351, 272 (1998).
Basilico, C., Arnesano, A., Galluzzo, M., Comoglio, P. M. & Michieli, P. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J. Biol. Chem. 283, 21267–21277 (2008).
Stamos, J., Lazarus, R. A., Yao, X., Kirchhofer, D. & Wiesmann, C. Crystal structure of the HGF β-chain in complex with the Sema domain of the Met receptor. EMBO J. 23, 2325–2335 (2004).
Shima, N. et al. Tumor cytotoxic factor/hepatocyte growth factor from human fibroblasts: cloning of its cDNA, purification and characterization of recombinant protein. Biochem. Biophys. Res. Commun. 180, 1151–1158 (1991).
Matteucci, E., Castoldi, R. & Desiderio, M. A. Hepatocyte growth factor induces pro-apoptotic genes in HepG2 hepatoma but not in B16-F1 melanoma cells. J. Cell. Physiol. 186, 387–396 (2001).
Mizuno, S., Matsumoto, K. & Nakamura, T. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J. 19, 580–582 (2005).
Tacchini, L., De Ponti, C., Matteucci, E., Follis, R. & Desiderio, M. A. Hepatocyte growth factor-activated NF-κB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis 25, 2089–2100 (2004).
Wang, X. et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol. Cell 9, 411–421 (2002).
Tulasne, D. et al. Proapoptotic function of the Met tyrosine kinase receptor through caspase cleavage. Mol. Cell. Biol. 24, 10328–10339 (2004).
Foveau, B. et al. Amplification of apoptosis through sequential caspase cleavage of the Met tyrosine kinase receptor. Cell Death Differ. 14, 752–764 (2007).
Potempa, S. & Ridley, A. J. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol. Biol. Cell 9, 2185–2200 (1998).
Rahimi, N., Hung, W., Tremblay, E., Saulnier, R. & Elliott, B. c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J. Biol. Chem. 273, 33714–33721 (1998).
Royal, I. & Park, M. Hepatocyte growth factor-induced scatter of Madin–Darby canine kidney cells requires phosphatidylinositol 3-kinase. J. Biol. Chem. 270, 27780–27787 (1995).
Khwaja, A., Lehmann, K., Marte, B. M. & Downward, J. Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway. J. Biol. Chem. 273, 18793–18801 (1998).
Sakkab, D. et al. Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL. J. Biol. Chem. 275, 10772–10778 (2000).
Xiao, G. H. et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl Acad. Sci. USA 98, 247–252 (2001).
Acknowledgements
The authors thank C. Boccaccio and their colleagues of the Laboratory of Molecular Pharmacology at IRCC, Torino, Italy, for comments and suggestions. Work in the authors' laboratory is funded by grants from: Associazione Italiana per la Ricerca sul Cancro (AIRC), Milano, Italy; European Union Framework Programmes; Regione Piemonte, Italy; Ministero dell'Università e della Ricerca, Italy; and Fondazione Piemontese per la Ricerca sul Cancro (FPRC), Italy.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Glossary
- Paracrine
-
Describing, or relating to, a regulatory cell that secretes a soluble molecule into an intercellular space, from which it diffuses to a nearby target cell other than the one that produces it.
- Reactive interstitial compartment
-
A connective tissue that responds to neighbouring stimuli such as inflammation and tumour formation or invasion.
- Src-homology-2 domain
-
(SH2 domain). A protein module that recognizes and binds tyrosine-phosphorylated sequences in a sequence-specific context and thereby has a key role in relaying cascades of signal transduction.
- GTPase-activating protein
-
(GAP). A protein that stimulates the intrinsic ability of a GTPase to hydrolyse GTP to GDP. GAPs negatively regulate GTPases by converting them from an active (GTP-bound) to an inactive (GDP-bound) state.
- Guanine nucleotide exchange factor
-
A protein that facilitates the exchange of GDP for GTP in the nucleotide-binding pocket of a GTPase.
- Pleckstrin homology domain
-
(PH domain). A protein domain that is characteristic of the RNase PH family of bacterial phosphate-dependent ribonucleases.
- Endosomal
-
Relating to a vesicle formed by invagination of the plasma membrane.
- Endocytosis
-
Internalization and transport of extracellular material and plasma membrane proteins from the cell surface to intracellular organelles known as endosomes.
- Focal complex
-
A small (1 μm diameter), dot-like adhesion structure that is present mainly at the edge of the lamellipodium.
- Focal adhesion
-
A cellular structure that links, through integrin receptors, the extracellular matrix outside the cell to the actin cytoskeleton inside the cell.
- E3 ubiquitin-protein ligase
-
An enzyme that is responsible for the conjugation of ubiquitin to substrate proteins.
- Multivesicular body
-
An endocytic intermediate organelle in the lysosomal degradative pathway that contains small vesicles and is surrounded by a limiting membrane.
- Proteasome
-
A large multisubunit protein complex that degrades unnecessary or damaged proteins by proteolysis.
- Placental labyrinth
-
The area of direct exchange between the fetal and maternal blood supply in the mammalian placenta.
- Hypaxial muscle
-
Skeletal muscle that is derived from progenitor cell populations that are located in the lateral myotome of each somite. Examples of hypaxial muscles include, among others, the diaphragm, the abdominal muscles and the muscles of the limb and girdles.
- Epithelial–mesenchymal transition
-
(EMT). The transformation of an epithelial cell into a mesenchymal cell that has migratory and invasive properties.
- Myofibroblast
-
A modified fibroblast with smooth muscle-like features and contractile properties.
Rights and permissions
About this article
Cite this article
Trusolino, L., Bertotti, A. & Comoglio, P. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11, 834–848 (2010). https://doi.org/10.1038/nrm3012
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrm3012
This article is cited by
-
Three Dimensional Bioprinting for Hepatic Tissue Engineering: From In Vitro Models to Clinical Applications
Tissue Engineering and Regenerative Medicine (2024)
-
Targeting the hedgehog pathway in MET mutation cancers and its effects on cells associated with cancer development
Cell Communication and Signaling (2023)
-
Hepatocyte growth factor pretreatment boosts functional recovery after spinal cord injury through human iPSC-derived neural stem/progenitor cell transplantation
Inflammation and Regeneration (2023)
-
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial
BMC Cancer (2023)
-
An mTOR feedback loop mediates the ‘flare’ (‘rebound’) response to MET tyrosine kinase inhibition
Scientific Reports (2023)